https://www.omisirge.cn/ 2025-12-08 monthly 1.0 https://d2xsxph8kpxj0f.cloudfront.net/310519663215159838/F3G5tFAiZrCKvc5smnLoVJ/omisirge-og-image-L6cS7pq4XEiK4Thx8VEMVY.png Omisirge® (omidubicel-onlv) — FDA批准的NAM技术脐带血干细胞疗法 首个且唯一获FDA批准用于严重再生障碍性贫血（SAA）及血液系统恶性肿瘤的细胞疗法。SAA：92%总生存率，0例慢性GvHD，11天植入。 https://www.omisirge.cn/about 2025-12-08 monthly 0.9 https://d2xsxph8kpxj0f.cloudfront.net/310519663215159838/F3G5tFAiZrCKvc5smnLoVJ/omisirge-og-image-L6cS7pq4XEiK4Thx8VEMVY.png 关于 Omisirge® — FDA批准的NAM技术造血干细胞疗法产品信息 Omisirge® 双适应症：严重再生障碍性贫血（SAA，≥6岁）及血液系统恶性肿瘤（≥12岁）。NAM技术扩增脐带血，92%总生存率，0例慢性GvHD。 Omisirge® 官方信息 zh 2025-12-08 Omisirge® (omidubicel-onlv) 获FDA批准用于严重再生障碍性贫血（SAA）— 完整产品信息 Omisirge, omidubicel, SAA, 严重再生障碍性贫血, NAM技术, 脐带血移植, GvHD, FDA批准, 造血干细胞移植 https://www.omisirge.cn/about/en 2025-12-08 monthly 0.9 https://d2xsxph8kpxj0f.cloudfront.net/310519663215159838/F3G5tFAiZrCKvc5smnLoVJ/omisirge-og-image-L6cS7pq4XEiK4Thx8VEMVY.png About Omisirge® — FDA-Approved NAM Technology Cord Blood Cell Therapy Omisirge® dual indications: Severe Aplastic Anemia (SAA, ≥6 years) and hematologic malignancies (≥12 years). 92% overall survival, 0 chronic GvHD, 11-day engraftment. Omisirge® Official Information en 2025-12-08 Omisirge® (omidubicel-onlv) FDA Approval for Severe Aplastic Anemia (SAA) — Complete Product Information Omisirge, omidubicel-onlv, severe aplastic anemia, SAA, cord blood transplant, NAM technology, GvHD, FDA approved, hematopoietic cell therapy, allo-HCT